Timing and determinants of erythropoietin deficiency in chronic kidney disease. - Wikidata - wikimedia - TriplyDB

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

http://www.wikidata.org/entity/Q35692480

about

Management of anemia in patients with diabetic kidney disease: A consensus statement Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease.The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease.Incident chronic kidney disease and newly developed complications related to renal dysfunction in an elderly population during 5 years: a community-based elderly population cohort study.A 3-marker index improves the identification of iron disorders in CKD anaemia.Association of Estimated Glomerular Filtration Rate with Hemoglobin Level in Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination Survey Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology.Physiology of the Renal Interstitium.Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa Paraneoplastic Erythrocytosis of Colon Cancer, with Serum Erythropoietin within the Normal Reference Range Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease.Increased Synthesis of Liver Erythropoietin with CKD.Iron deficiency across chronic kidney disease stages: Is there a reverse gender pattern?Anemia and low-grade inflammation in pediatric kidney transplant recipients.Neurohormonal and clinical sex differences in heart failure.Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.

P2860

Q26752692-7E50928A-4F68-4C58-B04F-4C89F65BA13A Q33583012-4412256B-E6D1-4604-B0D2-230EDDBD39D4 Q33825492-783886E3-733C-4436-B1B5-5E0A7AB7CB5A Q35075773-7E35DA25-A777-4DC2-897E-01C53BE0B73E Q35105827-0933BC65-DB90-49E6-A9E3-92DFEECC207B Q36003320-B7556DB7-7F0B-43F7-BCF4-E84BE911E3AA Q36054454-7B496D7F-953A-42C5-8270-3263F41AE932 Q36123584-3C4DB1E7-E88D-4C24-9CCB-5980FDB74EC8 Q36733554-D6699337-63E6-4571-8A86-8308C6CF0D14 Q37028926-B46A08DD-36E6-4A13-AE99-F76D6F24E99C Q37257340-52082734-DED2-4C04-9355-8DDBEB83E133 Q37685792-F8CA9D6C-9CB1-48C6-BCF2-17B8C9DA373B Q41849952-E3CA2313-5C7F-4B14-BEDB-588D0B70FC40 Q47550398-5E74F0D7-DC81-4391-AE11-13D9F5E09885 Q48088699-B0866BA9-C6A1-42E4-888D-E6D0DCD16DE4 Q51000455-9C0B5DD1-8067-4778-8B28-766C3E374C97 Q51546144-5435CFF7-0422-4C9D-97C8-83BE536763D7

P2860

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

http://www.wikidata.org/entity/Q35692480

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@ast

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@en

type

label

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@ast

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@en

prefLabel

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@ast

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@en

P1433

Q35692480-AD826BD3-4444-4BF6-97C5-A3EB76A7A59E

P1476

Q35692480-32F47F31-019A-41CD-A682-DDD850F42A74

P2093

Q35692480-0BC5FA75-A5AA-4B84-80EC-1974C73FA54D

Q35692480-4A299635-AF83-48E0-895E-DC3844B5BE6D

Q35692480-66E33FBA-D44E-43EB-B892-7F1E6327DBE0

Q35692480-6B1EABE1-F260-4D7E-AC19-0823526498C4

Q35692480-727C1D69-7865-4337-B118-BA90D254AD44

Q35692480-75FBB1DA-CD53-4FC8-8770-BABAC8EC237A

Q35692480-D479A4F5-AAC4-41FF-9200-B707CD66C0EF

Q35692480-DF7234E8-B10A-4059-918E-257F62F7B0EB

Q35692480-E06B980D-440B-494F-80EC-E070822F132C

P2860

Q35692480-00AB3200-0A37-4C2D-BB9B-3775460A4DA2

Q35692480-0FC932E5-A561-4F06-A6FE-6AE59B035122

Q35692480-15ED81EF-8A4F-43C9-A661-B6E95350A708

Q35692480-1637C2C6-36AF-48A1-BD88-80144B62FAA6

Q35692480-207BC26D-4C04-4243-8DB9-410B3A73B24B

Q35692480-20C8BB9F-EEC7-4C65-8803-8F648E769A02

Q35692480-248EFDA7-C42A-422A-9467-F0D5A08188A6

Q35692480-2ADBBBEE-F869-4E33-91CC-CEE00070BA3B

Q35692480-3DD6420B-1381-4277-8466-548756533A6A

Q35692480-43736A90-0809-4406-8873-520DC1291ED1

P304

Q35692480-28CB89EE-B269-463F-8CDB-B05A459B363D

P31

Q35692480-0C1689D8-D1EA-46E5-AA8E-32C940D1712C

P356

Q35692480-C51C329C-A641-4828-B804-F6354563CED8

P433

Q35692480-79F258E9-7E24-4111-95A0-04DD68D8240E

P478

Q35692480-8274FD90-7E2D-46BE-ADC2-E2F5633FE44D

P50

Q35692480-1F44F279-F17A-4103-BAE4-8DB84B24DB12

Q35692480-53B109C4-B9BB-403B-AF06-FEB2DE32A58F

P577

Q35692480-6681D27C-4E9F-46DC-AAE5-156D1DCB5F24

P5875

Q35692480-B434A1AD-5A9B-4CCC-B2D7-1799956B4508

P698

Q35692480-332728BA-10DD-4F75-A7DF-E7BB58F40DD6

P921

Q35692480-A9AFA483-1C99-4B79-BD11-E74A4A8AA133

P932

Q35692480-B2BFE1B6-68EE-416C-B857-0448BB17F1DD

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Timing and determinants of erythropoietin deficiency in chronic kidney disease.

@en

P2093

Alexandre Karras

http://www.w3.org/2001/XMLSchema#string

François Vrtovsnik

http://www.w3.org/2001/XMLSchema#string

Jean Philippe Haymann

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Boffa

http://www.w3.org/2001/XMLSchema#string

Lucile Mercadal

http://www.w3.org/2001/XMLSchema#string

Marie Metzger

http://www.w3.org/2001/XMLSchema#string

Martin Flamant

http://www.w3.org/2001/XMLSchema#string

NephroTest Study Group

http://www.w3.org/2001/XMLSchema#string

Nicole Casadevall

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Iron control of erythroid development by a novel aconitase-associated regulatory pathway.

Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias

Murine erythropoietin gene: cloning, expression, and human gene homology.

The effect of altitude on dosing and response to erythropoietin in ESRD

Timing of onset of CKD-related metabolic complications

Purification of erythropoietin.

Erythropoietin-dependent endothelial proteins: potential use against erythropoietin resistance.

Hypothesis: an erythropoietin honeymoon phase exists.

P304

35-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04690511

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Benedicte Stengel

P577

2011-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51811087

http://www.w3.org/2001/XMLSchema#string

P698

22096037

http://www.w3.org/2001/XMLSchema#string

P921

P932

3265349

http://www.w3.org/2001/XMLSchema#string